HSP90-IN-13 

HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway^[1].

HSP90-IN-13 (compound 5k) arrests the cell cycle on MCF-7 at a G2/M phase by 35.06% and induced apoptosis by 19.82%^[1].
HSP90-IN-13 has anti-proliferative activity against HCT-116, Hela and MCF-7 cell lines with IC₅₀s of 4.47 μM, 7.55 μM and 4.04 μM, respectively^[1].
HSP90-IN-13 has potent multi-target inhibitory activities against EGFR, VEGFR-2 and Topoisomerase-2 with IC₅₀ values of 38.5 nM, 126.95 nM and 25.85 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

483.54

C₂₆H₂₁N₅O₃S

2446055-29-2

O=C(C1=CC=CC(N2N=NC(CSC3=NC4=C(C(N3CC5=CC=CC=C5)=O)C=C(C)C=C4)=C2)=C1)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. El-Shafey HW, et al. Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: Promising antibreast cancer agent. Bioorg Chem. 2020 Aug;101:10398  [Content Brief]